Healthcare AI investing is full of hidden traps. Everyone gets fixated on clinical validation, FDA pathways, and go-to-market strategies, but it’s the boring operational details that can completely sink a portfolio company. Pear Therapeutics’ 2023 bankruptcy is a brutal, perfect lesson in this kind of concentration risk, showing how one point of failure, totally disconnected from the product’s quality or the market’s need, can trigger a company’s collapse almost overnight.
The Filing and the Unraveling
On April 7, 2023, Pear Therapeutics, once a big name in digital therapeutics, filed for Chapter 11 protection, ending a run that had included huge capital raises and major regulatory wins. The real story is in the declaration from their CFO/COO, Christopher Guiffre, filed with the SEC. Guiffre’s statement doesn’t blame the product or a change in the market. Instead, he lays out a financial implosion tied directly to the company’s banking setup and how it completely buckled under an outside shock. For any investor in this space, Guiffre’s declaration is required reading. It’s a raw look at how a simple operational weakness can destroy a company you thought was solid.
The Anatomy of Banking Concentration
Guiffre’s statement shows exactly how dependent Pear was on one bank: Silicon Valley Bank (SVB). They had six accounts with SVB (and only two with US Bank), and their Enterprise Resource Planning (ERP) system was wired directly into SVB’s payment platform. This tight integration seemed efficient, I’m sure, until it became a fatal weakness when SVB collapsed in March 2023. The moment SVB failed, Pear was cut off from all its operating cash. It wasn’t a slow burn, it was a sudden, total freeze that made it impossible to run the business. A company with advanced SaMD products and a solid data moat was suddenly unable to make payroll or pay its suppliers. The whole operation just seized up. This is a massive red flag for any investor doing diligence. You can’t just look at the cash balance on a spreadsheet. You have to ask where that cash is actually held and how fragile the company’s access to it really is. SEC EDGAR filing for Pear Therapeutics bankruptcy
The Letter-of-Credit Demands and the Vanishing Runway
Then it got worse. According to Guiffre, partners started demanding letters of credit. With SVB in freefall, counterparties got nervous and wanted guarantees that Pear could pay its bills. But a company can’t get a letter of credit when its primary bank has just failed. These demands for cash collateral hit at the exact moment Pear was locked out of its own bank accounts, creating a completely impossible situation. The company’s “runway”, the amount of time it had before running out of money, disappeared in an instant. With no access to their cash and facing immediate payment demands, they had no room to maneuver. Any chance of restructuring was gone. It all happened so fast, and it shows how your bank, your operational software, and your contracts are all linked in ways that can cause a total system failure from a single weak point.
Concentration Risk: The Primary Insolvency Variable
The Pear bankruptcy is the clearest example I’ve seen of concentration risk killing a healthcare AI company. Their SaMD products had FDA 510(k) clearances and were being used for real clinical problems, the bankruptcy record is very clear that the product didn’t fail. They had clinical validation and were making headway with payers. The company went insolvent because its over-reliance on a single bank turned into an operational disaster. This is so different from the usual startup post-mortems blaming poor product-market fit, a failed funding round, or getting stuck at the FDA. Pear had actually solved a lot of those problems and was a leader in its field. Their collapse shows that even a company with solid IP and a good data moat can be destroyed by something as basic as poor treasury management. For anyone investing in this sector, the Pear story means you have to dig into a company’s financial plumbing, not just its balance sheet and burn rate. Questions must extend to:
- Banking Diversity: How many banks are they using? Is all their operating cash sitting in one place? (And is that place a regional bank known for startup-friendly terms but questionable stability?)
- ERP Integration: How tightly is their financial software hooked into one specific bank? What’s the plan B if that connection breaks? How fast can they switch payment processing?
- Letter of Credit Exposure: What contracts do they have that could trigger a letter of credit demand? What happens if their main bank can’t issue one?
- Contingency Planning: Do they actually have a written plan for what to do if their bank fails? Have they tested it? The takeaway from Pear is that concentration risk is a real and present danger in healthcare AI, where financial controls often lag behind the pace of the science. It’s a variable you have to actively investigate and can’t just ignore. Understanding how a company can fail for non-product reasons is key to building a portfolio that can survive these kinds of shocks. Yes, the clinical data, regulatory strategy, and payer model are all still critical, but they mean nothing if the company’s basic financial operations are built on a single, fragile point of failure. Health Affairs article on digital therapeutics market challenges Overview of venture capital banking relationships
Frequently Asked Questions
What was the primary cause of Pear Therapeutics’ bankruptcy?
The primary cause of Pear Therapeutics’ bankruptcy was acute banking concentration risk, specifically its heavy reliance on Silicon Valley Bank (SVB). When SVB failed, Pear Therapeutics lost immediate access to its operating cash and faced unmeetable demands for letters of credit, leading to operational paralysis and insolvency.
Did Pear Therapeutics’ product efficacy or market demand contribute to its insolvency?
No, the article states that Pear Therapeutics’ insolvency was not due to product failure, lack of clinical validation, or inability to penetrate payer networks. The company had achieved significant regulatory milestones and its products addressed clinical needs, but its operational stability was undermined by financial vulnerabilities.
What specific banking concentration issues did Pear Therapeutics face?
Pear Therapeutics maintained six bank accounts with Silicon Valley Bank (SVB) and had its Enterprise Resource Planning (ERP) system integrated directly into SVB’s payment management system. This deep integration meant that SVB’s collapse immediately severed Pear Therapeutics’ access to its operating cash, leaving it without liquidity.
What lessons does the Pear Therapeutics bankruptcy offer investors regarding concentration and insolvency risk in healthcare AI?
The case highlights the critical importance of scrutinizing a company’s financial infrastructure beyond balance sheets. Investors should assess banking diversity, ensuring funds are not concentrated in a single institution, and understand the depth of ERP integration with banking partners to identify potential single points of failure.